Psychedelic therapy shows promise in mid-stage trial for treatment-resistant depression, with Beckley Psytech advancing BPL-003

Psychedelic therapy from Beckley Psytech shows promise for treatment-resistant depression based on newly released mid-stage trial data. In a Phase 2b study, Beckley’s compound BPL-003, an intranasal formulation of mebufotenin related to DMT, reduced symptoms on the MADRS scale at day 29 by 12.1 and 11.1 points depending on dose, versus a 5.8-point reduction in a low-dose comparator group. The trial included 193 participants and met its primary and key secondary endpoints. The report places Beckley’s results in a broader competitive and regulatory context, describing how psychedelic-therapy developers like Atai Life Sciences and Compass Pathways are moving toward commercialization while the U.S. policy environment appears to be shifting.